Paul Richardson, MD, concludes his conversation by briefly discussing additional trials influencing the multiple myeloma treatment landscape, as well as the use of iberdomide.
Paul Richardson, MD, director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, RJ Corman professor of medicine at Harvard Medical School, concludes his conversation by briefly discussing additional trials influencing the multiple myeloma treatment landscape, as well as the use of iberdomide.
Transcription:
0:09 | What we did look at in this study, which is important, is Duffy-null and we found that Duffy-null was present and 60% to 65% of our patients so far were African American. This may have implications for protein cytokine homeostasis and inflammatory signaling, as well as leukopenia. We are trying to figure all of that out. More to follow. But it is a very interesting and provocative presentation in that regard. Now, what about maintenance? Well, maintenance, obviously, duration of maintenance is established now, through DETERMINATION [NCT01208662], and building on that has been exemplified by the success of the FORTE [NCT02203643] and ATLAS [NCT02659293] studies, which have clearly shown that adding to it makes a big difference. And then, in that context, there are a number of trials that are building on this and going forward to look at the investment augmenting maintenance.
1:00 | I think what is important to share with you is that there are a large number of trials, and one of the most important is the integration of the new drug iberdomide. Then, there is also obviously, studies looking at [chimeric antigen receptor (CAR)] therapy and bispecifics, so really exciting data going forward, where cellular therapies are now establishing themselves in the transplant eligible patient population, in particular. [Minimal residual disease (MRD)]-directed alternative maintenance therapy approaches of ASH were impressively studied during the meeting. I have summarized them all here. I can tell you what one of the most interesting presentations was where the use of iberdomide post transplant dramatically improved complete response rates during the course of the first year of maintenance. I want to close that, and just thank you for your kind attention. It is a privilege to be able to share with you some of the highlights of ASH.
Care Teams Ease Inpatient/Outpatient Transitions in Multiple Myeloma
December 5th 2024Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance challenges, and multiple providers, highlighting the need for comprehensive care plans to ensure optimal outcomes.
Read More
FDA Accepts BLA for Belantamab Mafodotin Combinations in R/R Multiple Myeloma
November 25th 2024The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported by DREAMM-7 and DREAMM-8 data.
Read More
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More